Phenobarbital (PB) is used to treat generalized tonicclonic seizures, complex partial seizures and febrile convulsions, being effective at a serum concentration of 15-40 mg/ml. 1) Although monotherapy for seizures is preferable, improved control is sometimes achieved with concomitant therapy. The measurement of serum PB concentrations can be of value in individualizing dosage. It is clinically important to clarify the influences of antiepileptic drugs on the serum PB concentration in a steady-state (C t ).
Phenobarbital (PB) is used to treat generalized tonicclonic seizures, complex partial seizures and febrile convulsions, being effective at a serum concentration of 15-40 mg/ml. 1) Although monotherapy for seizures is preferable, improved control is sometimes achieved with concomitant therapy. The measurement of serum PB concentrations can be of value in individualizing dosage. It is clinically important to clarify the influences of antiepileptic drugs on the serum PB concentration in a steady-state (C t ).
When C t is related to the daily dose (D), the latter is often transformed to a variable (transformed daily dose: DЈ) being divided by an individual factor (transforming factor) such as total body weight (W) or body surface area. C t and D are expressed as a function of clearance, the transforming factor is thus used as a substitute for clearance. Then the influences of the coadministered antiepileptic drugs on PB disposition were evaluated by C t / DЈ(level/dose (L/D) ratio).
For PB, with W as a transforming factor, the L/D ratio (C t /(D/W): C t /DЈ W ) was found to be dependent on age. 2) Many reports have referred to changes in the C t /DЈ W ratio caused by other coadministered antiepileptic drugs, but there has been no regard paid to the influences of age. These results based on C t /DЈ W are misleading because patients might not be grouped by the age. For these reasons, if DЈ, which was related to C t without being affected by confounding factors such as age and gender, could be determined, it would be worth evaluating for clinical use. And it is preferable to clarify the relation between D and C t in the administration of PB alone. Then, the influence of concomitant drug use on the serum concentration could be evaluated in all the patients without grouping them by other confounding factors.
In this paper, the authors searched for suitable transforming factor affecting the L/D ratio of PB independent of confounding factors in the administration of PB alone, then clarified the relation between the daily PB dose and C t . In patients receiving concomitant therapy, the authors detected the drug affect on L/D ratio and investigated its influence quantitatively.
MATERIALS AND METHODS
We collected data from epileptic patients, who were chronically treated with multiple oral administrations of PB (Phenobal ® powders, Sankyo Co., Osaka, Japan) When there were multiple measurements for C t in one patient with the same prescribed drugs during the study period, the average value was used. The age, total body weight, height and daily PB dose were treated in the same manner. When several varieties of drugs were prescribed in one patient, the count was taken as the number of patients. In both hospitals, C t was measured in duplicate by the FPIA method (TDX ® or FLX ® system, DAINABOT, Tokyo Japan) and the average value employed.
Data analysis was performed by utilizing a statistical package, NAP (ver.4). Table 1 shows the characteristics of the study populations administered PB in each hospital. We combined the data from the two hospitals to elevate the power of tests in the analysis and to obtain various combinations of concomitant therapy.
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RESULTS
Patient Characteristics
PB Alone
Correlation of L/D Ratio with GENDER and AGE: Empirical formulas (1), (2) , and (3) have been reported for total body water volume (V TBW ), 5) body surface area (BSA), 6) and extracellular water volume (V ECW ), 5) respectively. The following transformed daily doses, DЈ W (ϭD/W), DЈ TBW (ϭD/V TBW ), DЈ BSA (ϭD/BSA), and DЈ ECW (ϭD/V ECW ), were proposed. The correlation of age with the L/D ratio was investigated for two groups, AGEϽ15 and AGE м15. C t /DЈ W , C t /DЈ TBW , and C t /DЈ BSA showed a significant difference between the two groups, but C t /DЈ ECW did not. In contrast, the L/D ratios showed no significant difference between genders ( Table 2) .
For example, C t /DЈ W and C t /DЈ ECW in relation to AGE are compared in Fig. 1 . The C t /DЈ W ratio showed a positive correlation with AGE for the groups of AGEϽ15 and all AGE (a). No significant correlation was found between C t /DЈ ECW and AGE in any group, that is, the C t /DЈ ECW ratio was independent of AGE (b). Factors Influencing C t : The data from the 326 patients were used for multiple regression analysis, with C t assigned as the criterion variable and DЈ W , DЈ TBW , DЈ BSA , or DЈ ECW as the main-explanatory variable. W, D, AGE, and GENDER were assigned as the sub-explanatory variables. The forward selection method was used to select the variables influencing C t . The level of significance, which prescribed the addition and/or elimination of a variable using the F-test, was taken as 0.05.
In Table 3 , the standard partial regression coefficients of the selected explanatory variables, namely the factors influencing C t , the simple correlation coefficient (r s ) between the main-explanatory variable and C t , and the multiple correlation coefficient (r m ) between all selected explanatory variables and C t are shown. In the transforming factor of W, V TBW and BSA, D or H was selected as the sub-explanatory variable, respectively. The difference between r m 2 and r s 2 indicates the contribution of the sub-explanatory variable to C t . In contrast, only the main-explanatory variable was selected in V ECW . That is, C t could be related only with the variable DЈ ECW . Figure 2 shows the relationship between C t and DЈ ECW . Both variables were significantly correlated and could be expressed approximately as line 1: C t ϭ0.989ϫDЈ ECW .
Concomitant Therapy Influence of One Drug on C t : It is comprehensible to investigate the influence of concomitant drug use by first examining the effect of one drug. Ninety-one patients were coadministered one antiepileptic drug such as valproic acid (VPA), carbamazepine (CBZ), phenytoin (PHT), or zonisamide (ZNS) ( Table 4 ). As shown in Fig. 2 of C t versus DЈ ECW was expressed approximately as the line 2 which intersected the origin for PBϩPHT. The same results were obtained with each of the other antiepileptic drugs (data not shown). From these results (Fig. 2) , the influence of the coadministered drug was evident from the change in the gradient of the regression line. We could thus compare each L/D ratio to detect the influence of another antiepileptic drug. In Table 4 , each alteration ratio is shown as the ratio of the L/D ratio of PB plus one drug to that of PB alone. The L/D ratio of PB alone was significantly increased by VPA, CBZ, and PHT (pϽ0.01). However, ZNS did not have an effect.
Influence of Antiepileptic Drugs on C t :
The L/D ratio rose significantly (pϽ0.05) as the number (Ϲ2) of drugs coadministered increased regardless of their type. The L/D ratio also increased with the concomitant use of 3 drugs as compared with 2 drugs (Fig. 3) .
DISCUSSION
There are reports that C t /(D/W) was increased significantly in children up to 15 years old. 2, 7) Before investing the influences of coadministered antiepileptic drugs on C t , it is preferable to clarify the relationship between the daily dose and C t for PB alone. Any confounding factors in this relationship should be excluded to evaluate the influences of antiepileptic drugs on C t . No gender-based differences were found at any L/D ratio. As a transforming factor was substituted for the clearance, gender differences were not found for clearance as observed for VPA. 8) On the other hand, when the L/D ratio was significantly different between two groups (AGEϽ15 and AGEм15), the age-dependent change in the transforming factor except for V ECW was not closely correlated with that in clearance. In our study population, the number of patients 15 years old or younger was sufficient and the ratio of C t /(D/V ECW ) was independent throughout the AGE (Fig. 1(b) ).
BSA is recommended as a transforming factor because of its close correlation with a number of age-dependent physiological parameters influencing the disposition of a drug such as renal blood flow and hepatic weight. 9) V ECW is also closely correlated to these parameters. 10 ) V ECW is a more suitable transforming factor for PB than W or BSA (Table 3) . Since most drugs distribute through the extracellular water space in order to reach their receptors, V ECW is more suitable for the ultimate drug level than BSA. For these reasons, we selected V ECW as a transforming factor.
In the present study, a significant linear relationship was found between C t and DЈ ECW , and concomitant therapy changed only the gradient of the regression line (Fig. 2) . The L/D ratio was increased because the coadministered drug raised the gradient for PB alone. VPA, CBZ, and PHT were found to raise the L/D ratio of PB (pϽ0.01) when they alone were coadministered (Table 4) . However, the number of patients coadministered one drug was not sufficient to detect any influence of the coadministered drugs, precisely.
Metabolism is the most important mechanism of elimination and accounts for drug interactions. The cytochrome P450 (CYP) system is the most important system for antiepileptic drugs.
11) The main metabolic pathway of PB is p-hydroxylation by CYP isoenzymes, possibly CYP2C19 and another important metabolic pathway is N-glucosidation. VPA inhibits both PB pathways and significantly reduces its metabolic clearance. 12) CBZ is an inducer of CYP2C9, but may be an inhibitor of CYP2C19 13) and studies on the effects of CBZ on PB showed a slight decrease in clearance. 14) CBZ may also slightly inhibit PB-metabolizing enzyme. PB and PHT are metabolized by the same enzyme system, they may each inhibit metabolism of the other by a competitive mechanism, 15) decreasing their metabolic clearance. ZNS does not affect CYP systems for PB metabolism.
13) Though significant differences were not observed, the L/D ratio of PB alone was slightly increased by ZNS.
The influences of these drugs on the L/D ratio as observed in Fig. 3 , were not additive and/or multiplicative. From these results of an increased L/D ratio and the competitive inhibition mechanism of these drugs between PB and its metabolizing enzyme, which was previously reported, we postulated that each coadministered drug competitively inhibits the PBmetabolizing enzyme.
Where E is the PB-metabolizing enzyme, I is the coadministered drug, k 0 is the binding rate constant, and k Ϫ0 is the dissociation rate constant. The deactivation ratio of the PBmetabolizing enzyme is postulated to be q on the left, and the residual activation ratio of the enzyme is 1Ϫq on the right. Then, the total enzyme activation is written as Et, and the following equations can be expressed from these concentrations.
The apparent equilibrium constant (h) can be written as then, the residual activation ratio (1Ϫq) can be written as 1/(1ϩh).
Next, in the case of two drugs coadministered, both drugs are distinguished by the subscript 1 and 2. The enzyme reactions are as follows.
Both coadministered drugs deactivate the PB-metabolizing enzyme competitively. The enzyme deactivation ratio is (1Ϫq 1 Ϫq 2 ) on the left of each equation and is q 1 and q 2 on the right. The residual enzyme activation ratio can be written as 1Ϫq 1 Ϫq 2 ϭ1/ (1ϩh 1 ϩh 2 ) , the same as when one drug is coadministered. Then, h 1 and h 2 can be written as q 1 /(1Ϫq 1 Ϫq 2 ) and q 2 /(1Ϫq 1 Ϫq 2 ), respectively.
Similarly, in the case where multiple drugs are coadministered, the residual enzyme activation ratio can be written as
where h i is written as q i /(1Ϫq 1 Ϫq 2 Ϫ···Ϫq i ) (n: number of coadministered drugs, iϭ1, 2, ···, n). The elimination rate constant of PB is proportional to the residual enzyme activity, and is given as (4) where (k el ) n and (k el ) 0 is the elimination rate constant with concomitant therapy and PB alone, respectively. The subscript i represents the drug coadministered, and iϭ1 to 6 corresponds to VPA, CBZ, PHT, ZNS, clonazepam (CZP), and ethosuximide (ETS), respectively. z i is 1 or 0 when drug i is or is not coadministered.
In the repetitive administrations, few errors would be caused by assuming that the daily amount of PB administered is equal to that eliminated. At a steady-state, the mass balance equation for PB in plasma can be expressed as Eq. 5.
where D is the daily PB dose [mg/d], F is the bioavailability [Ϫ], C f is the free-PB concentration in plasma [mg/ml], and V df is the distribution volume of free-PB [ l ] .
As C f and V df would be proportional to C t and V ECW , Eq. 6 can be written as
In Eq. 7, a is the constant [Ϫ] and C t /(D/V ECW ) is the L/D ratio. Equations 5 and 7 give C t /(D/V ECW ) as
We established Eq. 8 to elevate the power of the test and to better estimate the precise influence of each drug, quantitatively. (Table  5) . VPA, CBZ, and PHT were selected and would increase the L/D ratio to 1.466, 1.177, and 1.186 times the value for PB alone, respectively.
To evaluate each h i obtained in this study, measured and estimated concentrations were compared in cases where the drugs prescribed to the patient were changed. Both concentrations seem to be accurate (Fig. 4) . The mean prediction error (MPE) was calculated as 23.1% from the following equation.
MPE(%)ϭ{ S ( |measured value-estimated value| / measured value)/n}ϫ100 (n: number of sets compared) By elevating the power of the test and from the raised L/D ratio with the increase in the number of drugs coadministered (Fig. 3) , the authors postulated h i . As this model (Eq. 8) could analyze all cases inclusively, the reliability of the estimated values would be improved. As a result, VPA, CBZ, and PHT were found to raise the L/D ratio significantly. Even with an increase in patient number, ZNS was not found to influence the L/D ratio of PB. As shown in Tables 4 and 5 , estimated values closely corresponded to each other. These findings thus supported a competitive inhibition of these drugs for PB-metabolizing enzymes.
Our results were consistent with the reports that VPA, 16) and PHT 17) raised the L/D ratio on concomitant use. CBZ was reported to show a slight decrease in clearance 14) or no alterations 18) for PB. Though not clarified in our study, these evaluations might be affected the confounding factors. The result RϾ1 indicates that the coadministered antiepileptic drugs mainly lower the value of the elimination rate constant. These findings would also be due to the inhibition by these antiepileptic drugs. 19) It could not be clarified whether CZP and ETS had an effect or not because of an insufficient number of patients.
When the antiepileptic drugs administered to a patient are changed, the change in the L/D ratio can be estimated from Eq. 8 using the value of h i ( Table 5 ). In the case where the administration of VPA is added during therapy using PHT with PB, each L/D ratio is calculated as follows. 
Where L/D (0) is the L/D ratio of PB alone, L/D (3) and L/D (1, 3) mean the concomitant use of PHT and of VPAϩPHT, respectively.
From Eqs. 9 and 10, the alteration ratio of C t is given as the ratio of L/D (1, 3) to L/D (3) , thus, C t is expected to increase to 1.39 upon addition of VPA. The daily PB dose should be reduced to 0.72 (ϭ1/1.39) to maintain the same level of C t . Although the present study was retrospective and the clinical data were from a number of sources, we feel confident of the results (Fig. 4) . Many patients switch from PB treatment to mono/concomitant therapy. Each alteration ratio of R i , in our study population, could be adapted to all the patients without them being grouped by other confounding factors. This will make it easy to estimate C t correctly on the addition or discontinuance of co-treatment with antiepileptic drugs in PB therapy.
